Source link : https://newshealth.biz/health-news/linvoseltamab-promising-in-high-risk-smoldering-multiple-myeloma/
(MedPage Today) — TORONTO — Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 months among 19 evaluable… Source link : https://www.medpagetoday.com/meetingcoverage/ims/117570 Author : Publish date : 2025-09-20 18:53:00 Copyright for syndicated content belongs to the linked Source.
The post Linvoseltamab Promising in High-Risk Smoldering Multiple Myeloma first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-20 18:53:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8